Infinity Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Infinity Pharmaceuticals Inc faces competition from several companies in the market. Some key competitors include Novartis AG, Pfizer Inc, Bristol-Myers Squibb Company, and Merck & Co., Inc. These competitors operate in the same industry and may have similar products or services to offer. However, Infinity Pharmaceuticals Inc has its unique strengths and strategies that set it apart from its competitors. It is essential for investors and stakeholders to keep an eye on the competitive landscape to assess Infinity Pharmaceuticals Inc's market position and potential.

Infinity Pharmaceuticals Inc is a renowned biopharmaceutical company with a rich history and background. Established in 2001, Infinity Pharmaceuticals has been dedicated to discovering, developing, and delivering innovative medicines for patients in need. Over the years, the company has consistently made significant contributions in the field of oncology, particularly in targeted therapies. With a focus on precision medicine, Infinity Pharmaceuticals utilizes advanced research and development techniques to identify and exploit key biological pathways involved in cancer growth. By leveraging its expertise, the company strives to improve patient outcomes and enhance the quality of life for individuals affected by cancer.

Infinity Pharmaceuticals Inc. has achieved several significant milestones. Firstly, the company successfully developed IPI-549, a potentially groundbreaking treatment for cancer. They also secured a collaboration agreement with Roche to evaluate IPI-549 in combination with Roche's cancer immunotherapy drugs. Furthermore, Infinity Pharmaceuticals Inc. initiated several clinical trials to assess the efficacy and safety of IPI-549 in patients with various types of cancer. These milestones demonstrate the company's dedication to advancing cancer treatments and establishing valuable partnerships within the industry. Infinity Pharmaceuticals Inc. continues to make strides in their mission to improve the lives of patients suffering from cancer.

Infinity Pharmaceuticals Inc is primarily present in the United States of America.

Infinity Pharmaceuticals Inc represents values of innovation, excellence, and commitment to improving patients' lives. The company is dedicated to developing groundbreaking treatments for patients with unmet medical needs, particularly in the field of oncology. Infinity Pharmaceuticals Inc's corporate philosophy revolves around leveraging their expertise in drug discovery and development to advance novel therapies and deliver value to patients, healthcare providers, and stakeholders. By consistently pursuing scientific excellence, translating innovative ideas into potential therapies, and maintaining strategic collaborations, Infinity Pharmaceuticals Inc strives to make a meaningful impact on patients' lives and contribute to the advancement of cancer treatment options.

8 analysts currently rate the Infinity Pharmaceuticals stock: 0 recommend buying, 3 holding and 5 selling.

Infinity Pharmaceuticals Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Infinity Pharmaceuticals share trades at 0,00 EUR (0,00 USD).

The Infinity Pharmaceuticals share (INFIQ) is listed on 4 stock exchanges, including: NASDAQ (INFI), Frankfurt (I3F.F), München (I3F.MU), Düsseldorf (I3F.DU).

The business model of Infinity Pharmaceuticals is focused on developing innovative drug candidates for cancer treatment and testing them in various phases of clinical trials. The company focuses on drugs that target the proliferative signaling cascade of cancer cells in novel ways in order to selectively kill tumor cells. The company also collaborates with other pharmaceutical companies to accelerate the development of new drugs. Infinity Pharmaceuticals has a diverse pipeline of promising drug candidates, with IPI-549 being one of the most advanced drugs currently being tested in Phase 2 studies for the treatment of various types of cancer such as melanoma and breast cancer. Another promising drug, IPI-582, is currently in Phase 1 studies for the treatment of different types of cancer and has the potential to effectively inhibit tumor invasion and metastasis. In addition to its development and commercialization strategy, Infinity Pharmaceuticals conducts extensive research activities to identify new target molecules that play a role in the treatment of cancer. The success of Infinity Pharmaceuticals' business model is ensured by the company's strong commitment to researching and developing innovative cancer therapies. The extensive product pipeline and collaborations with other companies also provide a solid foundation for future growth. In conclusion, the business model of Infinity Pharmaceuticals is focused on developing innovative drug candidates for cancer treatment and testing them in various phases of clinical trials. The company aims to provide better chances of survival and improved quality of life for cancer patients.

Liikevaihtoa ei voida laskea Infinity Pharmaceuticals:lle tällä hetkellä.

Voittoa ei voida laskea Infinity Pharmaceuticals:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Infinity Pharmaceuticals:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Infinity Pharmaceuticals:lle tällä hetkellä.

Infinity Pharmaceuticals:n Eulpool-laatuscore on 2/10.

Infinity Pharmaceuticals:n ISIN on US45665G3039. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Infinity Pharmaceuticals:n WKN on A0LA4Y. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Infinity Pharmaceuticals:n ticker on INFIQ. Tämä pörssinoteeraus käytetään Infinity Pharmaceuticals-osakkeiden kauppaan pörssissä.

Infinity Pharmaceuticals maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Infinity Pharmaceuticals kuuluu sektoriin 'Terveydenhuolto'.

Infinity Pharmaceuticals:n osingot jaetaan valuutassa USD.